Nucala

The U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.

The U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Nucala (mepolizumab) for the treatment of adult and pediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-hematologic secondary cause.

Positive results were reported from a pivotal Phase III trial assessing the safety and efficacy of Sanofi’s sutimlimab in people with primary cold agglutinin disease (CAD).

Novartis AG won U.S. approval for the company’s experimental sickle cell disease drug Adakveo.

Two months after winning approval from the U.S. Food and Drug Administration as an asthma treatment, GlaxoSmithKline is eying another potential regulatory win for Nucala following positive Phase III results in the treatment of patients living with hypereosinophilic syndrome (HES).

Novartis announced positive topline results from the Phase III REACH2 study evaluating Jakavi (ruxolitinib) in patients with steroid-refractory acute graft-versus-host disease.

Alexion Pharmaceuticals Inc. agreed to buy smaller biotech company Achillion Pharmaceuticals Inc. in a deal initially valued at $930 million.